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A B S T R A C T
Background: Asenapine (ASN) is approved in the United States as monotherapy and adjunctive therapy (to
lithium or valproate) in adults with bipolar mania, and as monotherapy in pediatric patients with bipolar mania.
This is the ﬁrst long-term study evaluating safety and tolerability of ASN ﬁxed doses in this population.
Methods: After completing a 3-week, randomized, placebo (PBO)-controlled acute trial, patients could enroll in
this 26-week, ﬁxed-dose (5 or 10 mg twice daily), double-blind extension study. Select predeﬁned treatment-
emergent adverse events (TEAEs) and metabolic parameters were reported.
Results: Overall, 164 patients were treated; 88 completed the study. The incidence of ≥1 TEAE was greater for
PBO/ASN 5 mg (68.3%) versus ASN 5 mg/ASN 5 mg (54.7%) and ASN 10 mg/ASN 10 mg (51.0%) with
sedation, headache, somnolence, akathisia, and dizziness occurring as the most prevalent TEAEs. Predeﬁned
TEAEs were more common for PBO/ASN 5 mg (33.3%) versus ASN 5 mg/ASN 5 mg (15.1%) and ASN 10 mg/
ASN 10 mg (15.7%). Weight gain (≥7% increase from baseline to endpoint) was more frequent for ASN 10 mg/
ASN 10 mg (16.3%) versus ASN 5 mg/ASN 5 mg (13.7%) and PBO/ASN 5 mg (8.9%). No clinically signiﬁcant
metabolic changes were observed. The incidence of serious AEs was low and primarily related to underlying
bipolar I disorder.
Limitations: This study lacked a comparator group and was not powered for direct comparisons of ASN
regimens. Results may not be applicable to the general bipolar population.
Conclusions: ASN was generally safe and well tolerated in adults with an acute manic or mixed episode
associated with bipolar I disorder.
1. Introduction
Bipolar disorder is a serious, psychiatric condition that can result in
marked functional impairment and a substantial reduction in quality of
life (Miller et al., 2014; Shippee et al., 2011; Sierra et al., 2005). Bipolar
disorder is also associated with excess mortality, in part due to a
signiﬁcantly increased risk of suicide (da Silva Costa et al., 2015;
LeardMann et al., 2013; Ösby et al., 2001). Major mood alterations
associated with bipolar I disorder include manic, depressive, or mixed
episodes that often fail to completely resolve, resulting in residual
mood symptoms and functional diﬃculties that linger between acute
episodes (American Psychiatric Association, 2000).
It is estimated that more than 90% of those who experience a single
manic episode will have future episodes (American Psychiatric
Association, 2000). These recurrent episodes can result in illness
progression, contributing to increased illness severity and burden
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(Post, 1992; Roy-Byrne et al., 1985). In 1990 and 2010, the US Burden
of Disease Collaborators ranked bipolar disorder (of which there are
several diﬀerent types, including bipolar I disorder) among the top 18
diseases in terms of years lived with disability (Murray et al., 2013).
Bipolar disorder represents a greater economic burden to society than
many other psychiatric disorders, entailing large direct medical costs
and even larger indirect costs such as lost productivity and the negative
impact extending to family/caregivers (Laxman et al., 2008; Peele
et al., 2003). Therefore, eﬀective long-term prevention of episodes is
essential to maintain quality of life and reduce burden on patients,
caregivers, and the healthcare system.
Current treatment options for bipolar I disorder have proven
inadequate for many patients. Although most patients symptomatically
recover from acute episodes, only a minority functionally recover. In
addition, tolerability issues contribute to patients being unable or
unwilling to continue treatment (McIntyre, 2011; McIntyre and
Konarski, 2005; Perlis et al., 2006; Tohen et al., 2003).
Consequently, there is a need for safe and tolerable treatment options
that also achieve syndromal, symptomatic, and functional recovery
(McIntyre, 2011).
Asenapine (ASN) is a fast-dissolving, rapidly absorbed, sublingual
atypical antipsychotic, initially approved by the US Food and Drug
Administration in adults with bipolar mania (in 2009 as monotherapy
and in 2010 as an adjunct to either lithium or valproate). In March
2015, ASN was approved for the treatment of pediatric patients with
bipolar mania. In addition, ASN is approved for both acute and
maintenance treatment of adults with schizophrenia. An initial phase
3, randomized, double-blind, multicenter, placebo (PBO)-controlled, 3-
week trial explored the dose–response relationship of ASN 5 and 10 mg
twice daily (bid) ﬁxed doses to determine the minimum eﬀective dose
in acute mania, with both doses demonstrating eﬃcacy in terms of
reducing both manic and depressive symptoms (Landbloom et al.,
2016). The objective of the current study was to evaluate the long-term
safety/tolerability of ASN 5 and 10 mg bid in adults with an acute
manic or mixed episode associated with bipolar I disorder.
2. Methods
Details of the phase 3b, international, double-blind, ﬁxed-dose,
parallel-group, 3-week PBO-controlled trial of ASN 5 and 10 mg bid in
adults with an acute bipolar I disorder manic or mixed episode
(NCT00764478) have been previously published (Landbloom et al.,
2016). After completing the acute trial, patients could enroll in the
present study, a 26-week, double-blind, ﬁxed-dose, multicenter, long-
term, phase 3b extension trial (NCT01395992) to evaluate the long-
term safety of ASN 5 mg and 10 mg bid in individuals with a diagnosis
of bipolar I disorder and acute manic exacerbation at the time of
enrollment in the acute trial (Fig. 1). The current trial consisted of a
baseline visit (day 21/end of treatment for the prior 3-week acute trial),
an extension treatment period of 26 weeks, and a follow-up period. The
ﬁrst day of this extension trial overlapped with day 21/end of treatment
for the prior acute mania trial.
The trial was conducted from May 9, 2012, to December 3, 2014, at
38 centers in the United States, Bulgaria, Russia, Croatia, and Ukraine.
Diagnosis of bipolar I disorder with a current manic or mixed episode
was made according to the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, Text Revision [DSM-IV-TR] (American
Psychiatric Association, 2000), at entry into the prior acute mania
trial. Independent ethics committees associated with each study site
reviewed and approved the protocol and applicable amendments. The
trial was conducted in conformance with good clinical practice guide-
lines and applicable country and/or local statutes and regulations
regarding ethical committee review, informed consent, and the protec-
tion of human subjects participating in biomedical research. Written
informed consent for the extension trial was provided by patients
before performing any study-speciﬁc assessments unique to the exten-
sion trial (separate informed consent was signed for any baseline
procedures that were performed as part of the end-of-trial visit for the
acute mania trial). Patients could withdraw consent at any time for any
reason and, if deemed necessary, the investigator or subinvestigator
could discontinue patients. Discontinuation was permanent and pa-
tients who discontinued the study were not replaced. Concomitant
medications were coded using the most recent version of the World
Health Organization drug dictionary (March 2014) at the time of
database lock.
2.1. Inclusion criteria
Patients aged ≥18 years who completed the prior acute mania trial
and were considered likely to beneﬁt from continued treatment
(whether or not they had shown improvement during the acute trial)
were eligible for enrollment in the extension trial. A key inclusion
criterion from the prior acute trial was a diagnosis at entry of bipolar I
disorder with a current manic or mixed episode according to the DSM-
IV-TR. For enrollment in the extension trial, patients were required to
demonstrate an acceptable degree of adherence with trial medication,
visits, and other requirements in the acute trial, and have a person
considered reliable who agreed to act as a contact person for the patient
during the trial. In addition, patients must have agreed not to begin
formal, structured psychotherapy targeting the symptoms of bipolar I
disorder during treatment in the trial.
2.2. Exclusion criteria
Patients with an uncontrolled, unstable, clinically signiﬁcant med-
ical condition that may interfere with interpretation of safety/toler-
ability and eﬃcacy evaluations were excluded from the trial, as were
those with any newly diagnosed or discovered medical condition that
would have excluded the patient from participation in the acute trial.
Also excluded were those with any newly diagnosed psychiatric
condition that would have excluded the patient from participation in
the acute trial, such as a primary Axis I disorder other than bipolar I
disorder. Patients with any other clinically signiﬁcant situation that
would interfere with the trial evaluations or optimal trial participation,
or any occurrence(s) of an adverse event (AE) or other clinically
signiﬁcant ﬁndings in the acute mania trial that would prohibit
continuation in the long-term extension trial also were excluded.
Additional criteria that warranted exclusion included having any of
the following at baseline of the extension study: a Clinical Global
Impression scale for Bipolar Disorder, Overall Severity (CGI-BP-OS)
score ≥6 (severely ill); a positive serum pregnancy test or intention to
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Fig. 1. Study design. Day 21 refers to day 21 of the acute mania trial; Day 1 refers to day
1 of the extension trial. ASN, asenapine; bid, twice daily; EOT, end of treatment; FU,
follow-up; PBO, placebo.
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become pregnant during the long-term extension trial; meeting DSM-
IV-TR criteria for substance abuse or dependence (excluding nicotine)
within the time period from 6 months prior to the acute trial and
extension study baseline; a diagnosis of a psychotic disorder or a
behavioral disturbance thought to be substance induced or due to
substance abuse; imminent risk of self-harm or harm to others; a
history of imprisonment, parole, or assaultive behavior within the prior
2 years; current involuntary inpatient commitment; and symptoms
suggesting allergy or sensitivity to ASN in the acute trial. Current use of
antipsychotics (other than trial medication), St John's Wort and other
herbal supplements for the treatment of psychiatric symptoms, antie-
metics containing a dopamine antagonist, illicit drugs, stimulants,
medium- and long-acting benzodiazepines, psychotherapy, and elec-
troconvulsive therapy also were grounds for exclusion.
2.3. Procedures
An interactive voice response system was used to assign unique
patient identiﬁcation numbers for the current study, maintain the
blinding from the acute trial, and track patient enrollment and
retention. In addition, the packaging and labeling of the trial medica-
tion maintained the double-blind design of the trial. Trial medication
included two diﬀerent doses of active fast-dissolving ASN tablets,
which were made to look identical in appearance. Neither the patient
nor the investigational staﬀ were aware of which treatment the patient
received. Patients taking double-blind ASN 5 or 10 mg bid at the end of
the prior acute mania trial were assigned to continue in the same
regimen in the 26-week extension trial. Patients randomly assigned to
PBO in the prior acute mania trial were allocated to double-blind ASN
5 mg bid in the 26-week extension trial.
Patients were contacted on day 2 of the extension trial to ensure
they understood the instructions for dosing and how to assess AEs.
Patients had clinical research visits at baseline and weeks 1, 2, 4, 8, 12,
16, 20, and 26, with additional visits scheduled to assess safety,
tolerability, and illness severity as required. Patients were contacted
weekly via telephone between visits. Upon completion or discontinua-
tion of the trial, patients had a follow-up visit 7 days after their ﬁnal
dose of ASN; 30 days after trial completion/discontinuation, each
patient was telephoned to establish whether any serious adverse events
(SAEs) or pregnancies had occurred and to update the status of
unresolved AEs/SAEs.
2.4. Safety outcomes
AEs (coded using the most recent Medical Dictionary for
Regulatory Activities [MedDRA] at time of database lock, MedDRA
version 17.1) were reported from extension-trial baseline through last
date of trial medication intake +7 days. SAEs were reported from
baseline through last date of trial medication +30 days. AEs were
designated as treatment-emergent adverse events (TEAEs) for new or
worsening reported events after the extension-trial baseline. Select
prespeciﬁed TEAEs of interest based on ASN drug class were mon-
itored throughout the study and included: the combination of somno-
lence, sedation, and hypersomnia; dizziness; insomnia; oral hypoesthe-
sia combined with dysgeusia; akathisia; extrapyramidal symptoms
(EPS); and a predeﬁned limit of change (PDLC) of body weight at
endpoint (i.e., ≥7% increase from baseline). Other TEAEs occurring in
≥5% of patients were reported and additional safety assessments
included laboratory tests, vital signs, SAEs, AEs, weight/abdominal
girth, physical examination, electrocardiograms, Abnormal Involuntary
Movement Scale, EPS (using Barnes Akathisia Scale and Simpson
Angus Rating Scale), and Columbia Suicide Severity Rating Scale.
2.5. Eﬃcacy outcomes
No eﬃcacy hypothesis was tested, and there were no primary
eﬃcacy parameters as this study lacked a PBO control group. However,
the following exploratory eﬃcacy endpoints, based on the primary and
secondary endpoints in the prior acute trial, were assessed during the
study: change from acute trial baseline in Young Mania Rating Scale
(YMRS) total score, the rate of YMRS response (≥50% reduction from
acute trial baseline), the rate of YMRS remission (ﬁnal total score ≤12),
change from acute trial baseline in CGI-BP-OS score, and the rate of
Clinical Global Impression-Bipolar Mania-Improvement (CGI-BP-I) of
Overall Bipolar Illness response. CGI-BP-I was compared with the
impression of severity of illness at acute trial baseline, which served as
the pretreatment reference level against which changes that occurred
while taking trial medication were measured. A patient was considered
a CGI-BP-I responder if, when compared with acute trial baseline, the
change was measured as minimally improved, much improved, or very
much improved.
2.6. Sample size
Sample size was determined by the number of patients who
completed the acute trial and who continued into the current trial.
All eligible patients completing the acute trial and who may beneﬁt
from treatment with ASN were able to participate in this trial. Based on
the projection that 70% of the 366 patients randomized in the acute
trial would complete the study and that 90% of those patients would
enroll in the long-term extension trial, 230 patients were predicted to
enroll in the extension study.
2.7. Data presentation
For presentation purposes, both the acute and extension trial
treatments were included in treatment group labels: PBO/ASN 5 mg
indicates those patients allocated to PBO in the acute trial who were
subsequently allocated to ASN 5 mg bid in the extension trial; ASN
5 mg/ASN 5 mg indicates those patients taking ASN 5 mg bid at the
end of the acute trial who continued to take ASN 5 mg bid in the
extension trial; ASN 10 mg/ASN 10 mg indicates those patients taking
ASN 10 mg bid at the end of the acute trial who continued to take ASN
10 mg bid in the extension trial. In addition to these three treatment
groups, all patients treated with ASN 5 mg bid in the extension trial
were combined for evaluation as an additional treatment arm (ASN
5 mg overall).
2.8. Statistical analysis
For the evaluation of safety/tolerability and eﬃcacy endpoint
continuous variables, analysis of covariance was used. Point estimates
and 95% conﬁdence intervals (CIs) were obtained by treatment group
and visit, with the baseline value and investigative site (or pooled site)
as covariates. No P values were presented. For safety/tolerability and
eﬃcacy endpoint categorical variables, adjusted proportions of patients
who experienced each endpoint were calculated. Analyses were per-
formed by treatment group and visit, with adjustment for investigative
site (or pooled site). Variance and conﬁdence intervals for each
treatment group were calculated. Demographic variables were sum-
marized by treatment group and overall for the All Treated Set (ATS)
and Full Analysis Set (FAS) populations. Previous and/or current
psychiatric diagnosis and bipolar I disorder psychiatric history were
summarized by treatment group and overall for the ATS population.
There were no prespeciﬁed key safety/tolerability endpoints or
hypothesis testing of safety/tolerability data, and all safety/tolerability
analyses used the ATS population, which by deﬁnition included all
patients who received ≥1 dose of the extension trial medication.
Analysis was performed under the treatment group that the patients
actually received; the single patient for whom blinding was broken in
the acute trial was not excluded from the ATS population. Changes
from extension trial baseline analyses were relative to the ﬁrst day of
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the extension trial/last day (day 21) of the acute mania trial unless
otherwise noted (i.e., ≥7% weight increase). Summary statistics
reﬂected the extension trial period only. The analysis of safety data
followed a tiered approach with the tiers diﬀering with respect to the
analyses that were performed.
Tier 1 safety/tolerability endpoints were safety/tolerability para-
meters or TEAEs of special interest that were identiﬁed a priori/
predeﬁned by drug class. Tier 1 endpoints included the combination of
somnolence, sedation, and hypersomnia; dizziness; insomnia; oral
hypoesthesia combined with dysgeusia; akathisia; EPS; and a PDLC
of body weight (i.e., ≥7% increase from baseline). TEAEs and PDLCs
that were not prespeciﬁed as Tier 1 endpoints were classiﬁed as Tier 2
or Tier 3. Tier 2 TEAEs included change from baseline to study
endpoint in fasting glucose, fasting triglycerides, fasting cholesterol,
prolactin, fasting insulin, glycosylated hemoglobin, and speciﬁc TEAEs
with incidence of ≥4 patients in any treatment group. Tier 3 TEAEs
included all other AEs and PDLCs. Tier 1 and Tier 2 parameters were
assessed via point estimates with 95% CIs; only point estimates by
treatment group were provided for Tier 3 parameters. Descriptive
(rather than inferential) statistics were performed for all tiers.
Postbaseline values for changes in vital signs and body weight were
ﬂagged as potentially clinically relevant if PDLCs were met. PDLCs
were deﬁned as: pulse, sitting=change of ≥15 bpm from acute trial
baseline (≥120 bpm or ≤50 bpm); systolic blood pressure, sitting=-
change of ≥20 mmHg from acute trial baseline (≥180 mmHg or
≤90 mmHg); diastolic blood pressure, sitting=change of ≥15 mmHg
from acute trial baseline (≥105 mmHg or ≤50 mmHg); and body
weight=change of ≥7% from acute trial baseline.
Exploratory statistical analyses of eﬃcacy endpoints were summar-
ized by treatment group, and baseline analyses were relative to the
acute trial baseline. Summary statistics reﬂected data from the exten-
sion trial treatment period only; the baseline visit from the acute trial
was also included. All eﬃcacy analyses used the FAS, deﬁned as all
randomized patients from the acute trial who received ≥1 dose of the
extension trial medication and had ≥1 postbaseline YMRS total score
measurement. Analysis was performed by the treatment group patients
were randomized to in the acute trial, and patients for whom blinding
was broken were not excluded from the FAS population. Descriptive
statistics were summarized by treatment group. For each postbaseline
visit in which the applicable measures were assessed, the change from
both baselines was calculated by both observed case (OC) and last
observation carried forward (LOCF) methods.
3. Results
3.1. Patients
Of the 264 patients (placebo, n=93; ASN 5 mg, n=87; ASN 10 mg,
n=84) who completed the acute trial, 165 patients continued into this
extension study; 164 were treated and included in the ATS and 161
were included in the FAS (Fig. 2). Of the 165 enrolled patients, 88
(53.3%) completed the full treatment phase of the study, with similar
numbers completing across treatment groups. A total of 55 ASN-
treated patients (53%; 29 ASN 5 mg and 26 ASN 10 mg) and 33 PBO-
treated patients (55%) completed treatment in the extension trial. Non-
compliance with the study protocol was the most common single
reason for discontinuation across all treatment groups (20.0%),
followed by AEs (10.3%) and those lost to follow-up (6.7%). Among
those patients who discontinued owing to AEs, psychiatric disorders
were the most common cause.
Fig. 2. Patient disposition. The All Treated Set (ATS) population includes randomized patients from the acute trial who received ≥1 dose of the extension trial medication. The Full
Analysis Set (FAS) population is deﬁned as all randomized patients from the acute trial who received ≥1 dose of extension trial medication and had ≥1 postbaseline Young Mania Rating
Scale total score measurement. AE, adverse event; ASN, asenapine; ATS, All Treated Set; BPD, bipolar I disorder; PBO, placebo.
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Baseline characteristics were well matched between treatment
groups (Table 1). The mean age of all patients who received ≥1 dose
of study medication was 44.4 ± 10.4 years, and there were more female
than male patients (54.3% vs 45.7%). Overall, upon entry to the prior
acute mania trial, 93 (56.7%) and 71 (43.3%) patients met the DSM-
IV-TR criteria for manic and mixed episodes of bipolar I disorder,
respectively, and the mean duration of bipolar I disorder was 13.9 ± 8.6
years. Between 75% and 82% of patients in each treatment group
received concomitant medications during the extension study.
Supplemental Table 1 lists the most common concomitant medications
by ATC class and preferred term and the number of patients receiving
each.
3.2. Safety/tolerability
No deaths were reported during the trial. Eight patients experi-
enced severe TEAEs: 3 (5.0%) in the PBO/ASN 5 mg group, 2 (3.8%) in
the ASN 5 mg/ASN 5 mg group, and 3 (5.9%) in the ASN 10 mg/ASN
10 mg group. Five patients experienced ≥1 SAE: 3 (5.0%) in the PBO/
ASN 5 mg group, 0 (0.0%) in the ASN 5 mg/ASN 5 mg group, and 2
(3.9%) in the ASN 10 mg/ASN 10 mg group. Most SAEs (3/5) belonged
to the psychiatric disorders class and were related to the patient's
underlying bipolar I disorder. One patient (in the ASN 10 mg/ASN
10 mg group) experienced a cardiac SAE. On study day 21, this patient,
a 42-year-old white male, had chest pain and was hospitalized; this
patient recovered and was released from the hospital on study day 27.
ASN was discontinued due to lack of eﬃcacy and the last dose was
administered on study day 57. Another patient (in the PBO/ASN 5 mg
group) experienced a hepatobiliary SAE. On study day 22, this patient,
a 50-year-old white female, was hospitalized for a gall bladder attack;
this event resolved and the patient was discharged from the hospital on
study day 23. ASN was not discontinued and the patient completed the
study per protocol. The proportion of patients who discontinued
treatment due to AEs was similar in the PBO/ASN 5 mg (11.7%),
ASN 5 mg/ASN 5 mg (11.3%), and ASN 5 mg overall (11.5%), groups,
and slightly lower for the ASN 10 mg/ASN 10 mg group (7.8%).
Psychiatric and nervous system disorders leading to treatment dis-
continuation were reported in all three individual treatment groups
(5.0% PBO/ASN 5 mg, 5.7% ASN 5 mg/ASN 5 mg and 7.8% ASN
10 mg/ASN 10 mg).
Overall, the incidence of TEAEs was greater in the PBO/ASN 5 mg
group (68.3% with ≥1 TEAE) compared with the ASN 5 mg/ASN 5 mg
(54.7%) and ASN 10 mg/ASN 10 mg (51.0%) groups. The most
prevalent TEAEs were those classiﬁed as Nervous System disorders,
with 39 patients experiencing TEAEs within this class: 31.7% (19/60)
patients in the PBO/ASN 5 mg group, 22.6% (12/53) patients in the
ASN 5 mg/ASN 5 mg group, and 15.7% (8/51) patients in the ASN
10 mg/ASN 10 mg group. In general, Tier 1 TEAEs were more common
in the PBO/ASN 5 mg treatment group (Table 2). The Tier 1 event of
dizziness was reported only in the PBO/ASN 5 mg treatment group
(5.0%, 3/60). A dose-dependent eﬀect among Tier 1 TEAEs was not
evident. Tier 1 SAEs/AEs leading to treatment discontinuation in-
cluded somnolence (in 1 patient [1.9%] in the ASN 5 mg/ASN 5 mg
group and 1 patient [2.0%] in the ASN 10 mg/ASN 10 mg group) and
sedation (in 1 patient [1.7%] in the PBO/ASN 5 mg group).
Weight gain (≥7% increase from acute trial baseline to endpoint)
was more frequent in the ASN 10 mg/ASN 10 mg group compared with
the other treatment groups (Table 2). Weight gain was reported as a
TEAE for 2 patients (one in the PBO/ASN 5 mg group and one in the
ASN 5 mg/ASN 5 mg group).
Tier 2 TEAEs were most commonly reported in the PBO/ASN 5 mg
treatment group, with 40.0% of patients reporting ≥1 Tier 2 TEAE
compared with 32.1% in the ASN 5 mg/ASN 5 mg group and 27.5% in
the ASN 10 mg/ASN 10 mg group (Table 2). The most common Tier 2
Table 1
Demographic and clinical characteristics (ATS).
Characteristics PBO/ASN 5 mg n=60 ASN 5mg/ ASN 5mg
n=53
ASN 5 mg overall
n=113
ASN 10 mg/ ASN
10 mg n=51
Total N=164
Sex, n (%)
Male 28 (46.7) 25 (47.2) 53 (46.9) 22 (43.1) 75 (45.7)
Female 32 (53.3) 28 (52.8) 60 (53.1) 29 (56.9) 89 (54.3)
Race, n (%)
White 24 (40.0) 26 (49.1) 50 (44.2) 28 (54.9) 78 (47.6)
Black 29 (48.3) 24 (45.3) 53 (46.9) 23 (45.1) 76 (46.3)
Other 7 (11.7) 3 (5.7) 10 (8.8) 0 (0.0) 10 (6.1)
Age category, n (%)
18 to 64 years 58 (96.7) 53 (100.0) 111 (98.2) 50 (98.0) 161 (98.2)
≥65 years 2 (3.3) 0 (0.0) 2 (1.8) 1 (2.0) 3 (1.8)
Age (y), mean (SD) 43.9 (10.9) 44.8 (9.6) 44.4 (10.3) 44.6 (10.7) 44.4 (10.4)
Weight (kg), mean (SD) 86.2 (17.4) 84.4 (18.8) 85.4 (18.0) 83.5 (15.8) 84.8 (17.3)
BMI (kg/m2), mean (SD) 29.8 (5.3) 29.4 (5.9) 29.6 (5.5) 29.3 (5.2) 29.5 (5.4)
Principal diagnosis, n (%)a
Manicb 35 (58.3) 28 (52.8) 63 (55.8) 30 (58.8) 93 (56.7)
Mixedc 25 (41.7) 25 (47.2) 50 (44.2) 21 (41.2) 71 (43.3)
Duration of bipolar disorder (y), mean
(SD)
13.7 (7.8) 13.8 (9.5) 13.7 (8.6) 14.4 (8.6) 13.9 (8.6)
Duration of current episode, n (%)
< 1 week 3 (5.0) 4 (7.5) 7 (6.2) 2 (3.9) 9 (5.5)
1 to < 2 weeks 16 (26.7) 17 (32.1) 33 (29.2) 17 (33.3) 50 (30.5)
2 to < 3 weeks 25 (41.7) 15 (28.3) 40 (35.4) 18 (35.3) 58 (35.4)
3 to ≤4 weeks 16 (26.7) 16 (30.2) 32 (28.3) 14 (27.5) 46 (28.0)
> 4 weeks 0 (0.0) 1 (1.9) 1 (0.9) 0 (0.0) 1 (0.6)
ASN, asenapine; ATS; All Treated Set; BMI, body mass index; PBO, placebo; SD, standard deviation.
a This information was captured during the acute trial screening period.
b Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) category 296.4x.
c DSM-IV-TR category 296.6x.
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TEAEs overall were: sedation, upper respiratory tract infection, head-
ache, and somnolence. The TEAE of oral hypoesthesia was reported
only in patients in the PBO/ASN 5 mg group (5 patients, 8.3%). At least
1 Tier 3 TEAE was reported by 46.7% of patients in the PBO/ASN 5 mg
group, 43.4% of patients in the ASN 5 mg/ASN 5 mg group, and 37.3%
of patients in the ASN 10 mg/ASN 10 mg group (Table 2).
A summary of mean metabolic, lipid, and endocrine parameters at
acute study baseline, extension baseline, and endpoint is presented in
Table 3. From extension trial baseline to endpoint, increases were
observed in mean levels of prolactin across all treatment groups with
the largest increase in the ASN 10 mg/ASN 10 mg group. Prolactin
levels > 4 times the upper limit of normal (PDLC for prolactin) were
observed in 3 patients (one in the PBO/ASN 5 mg group and two in the
ASN 10 mg/ASN 10 mg group). No TEAEs related to prolactin
abnormalities were reported. A mean increase in insulin was observed
in the ASN 10 mg/ASN 10 mg group, but not the ASN 5 mg/ASN 5 mg
group. Mean increases also were observed across all groups for glucose
and in the ASN 5 mg/ASN 5 mg and ASN 10 mg/ASN 10 mg groups for
fasting triglycerides.
3.3. Eﬃcacy
Mean changes in eﬃcacy parameters at acute trial baseline,
extension baseline, and endpoint are summarized in Table 4. Change
in YMRS total score from the acute trial baseline in this uncontrolled
extension trial indicated that improvement in mania in the controlled
acute trial was maintained through the course of the uncontrolled
extension study and was similar across treatment groups. The least-
squares (LS) mean change in OC YMRS total score from the acute trial
baseline to day 182 (extension-study endpoint) was −22.3 in the PBO/
ASN 5 mg group, −22.9 in the ASN 5 mg/ASN 5 mg group, and −22.0
in the ASN 10 mg/ASN 10 mg group.
Increases in OC YMRS responder rates from extension trial baseline
were +43.6% in the PBO/ASN 5 mg group, +38.0% in the ASN 5 mg/
ASN 5 mg group, and +26.0% in the ASN 10 mg/ASN 10 mg group.
Increases in OC YMRS remitter rates from extension trial baseline were
+43.3% in the PBO/ASN 5 mg group and +41.8% in the ASN 5 mg/
ASN 5 mg group, but were somewhat lower at +18.0% in the ASN
10 mg/ASN 10 mg group.
Change in CGI-BP-OS score from acute trial baseline in this
uncontrolled extension trial indicated that improvement in overall
severity of bipolar illness was maintained through the course of the
study and was similar across treatment groups. The LS mean change in
OC CGI-BP-OS scores from acute baseline to the extension trial study
endpoint were –2.3 in the PBO/ASN 5 mg group, –2.4 in the ASN
5 mg/ASN 5 mg group, and –2.3 in the ASN 10 mg/ASN 10 mg group.
An increase in OC CGI-BP-I overall response rates was seen in the
PBO/ASN 5 mg treatment group, although there was little notable
change from the extension trial baseline in the ASN 5 mg/ASN 5 mg or
ASN 10 mg/ASN 10 mg treatment groups. Shifts in incidence of OC
CGI-BP-I overall responders from extension trial baseline to study
endpoint were as follows: PBO/ASN 5 mg, +13.2%; ASN 5 mg/ASN
5 mg, −6.4%; ASN 10 mg/ASN 10 mg, −10.0%.
In general, ﬁndings with the LOCF approach were similar to those
using the above OC approach.
4. Discussion
Long-term treatment with ﬁxed doses of ASN (5 mg bid and 10 mg
bid) was generally safe and well tolerated in adults with an acute manic
or mixed episode associated with bipolar I disorder treated for up to 29
weeks. No new or emerging safety/tolerability signals were observed in
Table 2
Summary of key adverse experiences (ATS).
PBO/ASN
5 mg n=60
ASN 5mg/
ASN
5mg n=53
ASN
5 mg
overall
n=113
ASN
10 mg/
ASN
10 mg
n=51
Patients With Tier 1 TEAEs, n (%)a
≥1 Tier 1 TEAE 20 (33.3) 8 (15.1) 28 (24.8) 8 (15.7)
Tier 1 TEAEs
Somnolence,
sedation,
hypersomnia
combined
11 (18.3) 6 (11.3) 17 (15.0) 3 (5.9)
EPS 7 (11.7) 1 (1.9) 8 (7.1) 3 (5.9)
Akathisia 5 (8.3) 1 (1.9) 6 (5.3) 1 (2.0)
Oral hypoesthesia
combined with
dysgeusia
6 (10.0) 1 (1.9) 7 (6.2) 0 (0.0)
Insomnia 4 (6.7) 0 (0.0) 4 (3.5) 3 (5.9)
Dizziness 3 (5.0) 0 (0.0) 3 (2.7) 0 (0.0)
≥7% weight
increaseb
5 (8.9) 7 (13.7) 12 (11.2) 8 (16.3)
Patients With Tier 2 TEAEs, n (%)c
≥1 Tier 2 TEAE 24 (40.0) 17 (32.1) 41 (36.3) 14 (27.5)
Patients With Tier 3 TEAEs, n (%)d
≥1 Tier 3 TEAE 28 (46.7) 23 (43.4) 51 (45.1) 19 (37.3)
Patients With TEAEs, n (%)
≥1 TEAE 41 (68.3) 29 (54.7) 70 (61.9) 26 (51.0)
Patients With TEAEs (Incidence ≥ 5%, Occurring in ≥1 Treatment
Group), n (%)
Nervous system
disorders
Sedation 6 (10.0) 3 (5.7) 9 (8.0) 2 (3.9)
Headache 4 (6.7) 2 (3.8) 6 (5.3) 3 (5.9)
Somnolence 5 (8.3) 3 (5.7) 8 (7.1) 1 (2.0)
Akathisia 5 (8.3) 1 (1.9) 6 (5.3) 1 (2.0)
Dizziness 3 (5.0) 0 (0.0) 3 (2.7) 0 (0.0)
Gastrointestinal
disorders
Oral hypoesthesia 5 (8.3) 0 (0.0) 5 (4.4) 0 (0.0)
Diarrhea 0 (0.0) 1 (1.9) 1 (0.9) 3 (5.9)
Toothache 0 (0.0) 3 (5.7) 3 (2.7) 0 (0.0)
Psychiatric
disorders
Depression 0 (0.0) 4 (7.5) 4 (3.5) 3 (5.9)
Insomnia 4 (6.7) 0 (0.0) 4 (3.5) 3 (5.9)
Infections and
infestations
Upper respiratory
tract infection
7 (11.7) 2 (3.8) 9 (8.0) 2 (3.9)
Injury, poisoning
and procedural
complications
Accidental
overdose
4 (6.7) 2 (3.8) 6 (5.3) 2 (3.9)
Vascular disorders
Hypertension 1 (1.7) 3 (5.7) 4 (3.5) 1 (2.0)
ASN, asenapine; ATS, All Treated Set; EPS, extrapyramidal symptoms; PBO, placebo;
TEAE, treatment-emergent adverse event.
a Tier 1 TEAE, safety parameters, or AEs of special interest that were identiﬁed a
priori/predeﬁned by drug class.
b The denominator for percentages is the number of subjects with data at both
Baseline and Study Endpoint: PBO/ASN 5 mg, n=56; ASN 5 mg/ASN 5 mg, n=51; ASN
5 mg overall, n=107; ASN 10 mg/ASN 10 mg n=49.
c Tier 2 TEAE, change from baseline to study endpoint in fasting glucose, fasting
triglycerides, fasting cholesterol, prolactin, fasting insulin, and glycosylated hemoglobin,
and speciﬁc TEAEs with incidence of ≥4 patients in any treatment group.
d Tier 3 TEAE, all other AEs, and predeﬁned limits of change.
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Table 3
Summary of metabolic, lipid, and endocrine parameters (ATS).
Parameter PBO/ASN 5mg n=60 ASN 5mg/ASN 5 mg n=53 ASN 5 mg overall n=113 ASN 10 mg/ASN 10 mg n=51
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Prolactin, ng/mL
Acute Trial Baseline 58 11.9 (10.5) 53 13.6 (22.5) 111 12.7 (17.3) 50 9.4 (6.1)
Extension Baseline 58 8.6 (11.3) 50 21.4 (18.9) 108 14.5 (16.5) 51 23.8 (24.6)
Study Endpoint 55 15.1 (14.4) 50 17.6 (24.4) 105 16.3 (19.7) 49 22.3 (32.0)
Changea 55 3.2 (16.7) 50 3.6 (17.5) 105 3.4 (17.0) 49 12.7 (32.5)
Insulin, μU/mL
Acute Trial Baseline 58 18.7 (13.7) 53 29.4 (42.0) 111 23.8 (31.0) 49 18.5 (19.9)
Extension Baseline 58 15.5 (17.6) 51 23.4 (30.8) 109 19.2 (24.9) 49 21.2 (27.1)
Study Endpoint 55 20.2 (14.5) 48 29.8 (40.7) 103 24.7 (30.0) 49 28.0 (55.4)
Changea 55 0.6 (19.0) 48 −1.2 (50.3) 103 −0.2 (36.8) 48 10.2 (49.8)
Total Cholesterol, mg/dL
Acute Trial Baseline 58 186.7 (39.3) 53 198.7 (49.0) 111 192.5 (44.4) 50 197.9 (43.4)
Extension Baseline 58 181.3 (38.6) 50 197.2 (44.3) 108 188.6 (41.9) 51 192.3 (40.7)
Study Endpoint 55 180.1 (41.9) 50 201.3 (46.9) 105 190.2 (45.4) 50 195.8 (47.0)
Changea 55 −4.7 (30.7) 50 3.4 (35.3) 105 −0.9 (33.1) 50 −1.3 (32.8)
Fasting Triglycerides, mg/dL
Acute Trial Baseline 51 133.8 (108.1) 47 140.4 (83.6) 98 137.0 (96.7) 45 133.5 (71.2)
Extension Baseline 54 94.8 (45.0) 44 132.5 (92.4) 98 111.7 (72.4) 48 127.1 (66.2)
Study Endpoint 52 122.4 (75.4) 43 146.7 (86.7) 95 133.4 (81.2) 46 145.9 (86.9)
Changea 49 −9.5 (80.3) 41 9.0 (75.9) 90 −1.1 (78.5) 45 10.6 (62.9)
Glucose, mg/dL
Acute Trial Baseline 59 96.1 (14.6) 53 96.9 (18.1) 112 96.5 (16.3) 50 92.8 (15.8)
Extension Baseline 58 93.8 (16.5) 50 101.7 (32.3) 108 97.5 (25.3) 51 98.7 (18.3)
Study Endpoint 55 98.2 (15.0) 50 103.6 (31.4) 105 100.8 (24.2) 50 97.3 (15.5)
Changea 55 2.6 (14.9) 50 7.0 (29.4) 105 4.7 (23.0) 50 3.9 (16.3)
Glycosylated Hemoglobin, %
Acute Trial Baseline 58 5.5 (0.5) 53 5.5 (0.5) 111 5.5 (0.5) 50 5.4 (0.5)
Extension Baseline 58 5.5 (0.5) 51 5.6 (0.6) 109 5.6 (0.6) 51 5.5 (0.5)
Study Endpoint 54 5.5 (0.4) 50 5.7 (1.3) 104 5.6 (1.0) 48 5.5 (0.4)
Changea 54 0.0 (0.3) 50 0.2 (1.1) 104 0.1 (0.8) 48 0.0 (0.4)
ASN, asenapine; ATS, All Treated Set; PBO, placebo.
Acute Trial Baseline: last non-missing assessment prior to the first dose of acute trial medication.
Extension Baseline: last non-missing assessment prior to the first dose of extension trial medication.
Study Endpoint: last non-missing post-baseline assessment on or prior to the last dose date +7 days.
a Change from acute trial baseline to study endpoint.
Table 4
Efficacy parameters at acute trial baseline, extension trial baseline, and study endpoint (FAS).
PBO/ASN 5mg ASN 5mg/ASN 5 mg ASN 10 mg/ASN 10 mg
YMRS Total Score N Mean (SD) N Mean (SD) N Mean (SD)
Acute Trial Baseline 59 29.8 (5.6) 52 28.3 (5.0) 50 31.4 (5.0)
Extension Trial Baseline 59 18.1 (10.7) 52 13.3 (8.6) 50 13.8 (8.9)
Endpoint 57 7.7 (7.1) 50 6.5 (7.2) 50 8.3 (7.7)
YMRS Responders N n (%) N n (%) N n (%)
Extension Trial Baseline 59 26 (44.1) 52 26 (50.0) 50 29 (58.0)
Endpoint 57 50 (87.7) 50 44 (88.0) 50 42 (84.0)
YMRS Remitters N n (%) N n (%) N n (%)
Extension Trial Baseline 59 20 (33.9) 52 23 (44.2) 50 25 (50.0)
Endpoint 57 44 (77.2) 50 43 (86.0) 50 34 (68.0)
CGI-BP-OS N Mean Overall Score (SD) N Mean Overall Score (SD) N Mean Overall Score (SD)
Acute Trial Baseline 59 4.4 (0.5) 52 4.5 (0.7) 50 4.7 (0.5)
Extension Trial Baseline 59 3.3 (1.1) 52 2.7 (0.9) 50 2.8 (1.1)
Endpoint 57 2.2 (1.1) 50 2.1 (1.1) 50 2.2 (1.2)
CGI-BP-I Responders N n (%) N n (%) N n (%)
Extension Trial Baseline 59 45 (76.3) 52 47 (90.4) 50 45 (90.0)
Endpoint 57 51 (89.5) 50 42 (84.0) 50 40 (80.0)
ASN, asenapine; CGI-BP-I, Clinical Global Impression-Bipolar Mania-Improvement; CGI-BP-OS, Clinical Global Impression-Overall Severity; FAS, Full Analysis Set; PBO, placebo; SD,
standard deviation; YMRS, Young Mania Rating Scale.
Acute Trial Baseline: Last non-missing assessment prior to first dose of acute trial medication.
Extension Trial Baseline: Last non-missing assessment prior to first dose of extension trial medication.
Endpoint: Last non-missing post-baseline assessment on or prior to last dose date +3 days.
YMRS Responders: subjects who experienced at least 50% decrease from acute trial baseline in YMRS total score at that visit.
YMRS Remitters: subjects having YMRS total score ≤12 at that visit.
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this long-term extension trial. The broad pattern of TEAEs and the
discontinuation rate due to them were similar to those seen during a
long-term trial of ASN in patients with schizophrenia or schizoaﬀective
disorder (Schoemaker et al., 2010). Sedation and somnolence were the
most commonly reported Tier 1 TEAEs, and may be treatment-limiting
in a minority of patients. Together with akathisia, headache, dizziness,
and oral hypoesthesia, these Tier 1 TEAEs occurred more frequently in
those patients who received PBO during the acute trial and ASN 5 mg
during the long-term extension compared with other treatment groups,
and did not appear to be dose-dependent. This suggests that some
TEAEs that occur upon treatment initiation may resolve over time. The
rate of treatment discontinuation due to AEs was similar across all
treatment groups suggesting that most patients are able to adhere to
their treatment regimen even at the higher dose of ASN. AEs leading to
discontinuation were most commonly Psychiatric and Nervous System
Disorders and were observed across all groups. No deaths occurred
during this long-term extension study, and most SAEs involved
Psychiatric Disorders related to the patient's underlying condition of
bipolar I disorder.
Overall, 12.8% of patients taking ASN experienced potentially
clinically signiﬁcant weight gain (≥7% increase in body weight at
endpoint compared with the acute trial baseline). There was a trend
towards a greater incidence of ≥7% weight increase in patients who
received ASN 10 mg/ASN 10 mg (16.3%) compared with other treat-
ment groups (PBO/ASN 5 mg group, 8.9%; ASN 5 mg/ASN 5 mg,
13.7%; ASN 5 mg overall, 11.2%). Among those who had weight gain
meeting the PDLC, the increase in weight was reported as a TEAE for 2
patients. From the extension trial baseline to endpoint, increases in
mean glucose and prolactin levels were seen for all treatment groups.
Prolactin increases were greatest in the ASN 10 mg/ASN 10 mg group,
although there was wide variability in these measurements as evi-
denced by the large standard deviations. Despite the observed increases
in mean prolactin levels, a low percentage of patients (1.8%, 3 of 164
patients) had values that met PDLC levels, and no TEAEs related to
prolactin abnormalities were reported in this study. Mean increases
also were observed in some groups with respect to fasting triglycerides
and insulin, whereas total cholesterol was increased in the ASN 5 mg/
ASN 5 mg group alone.
Over the course of this 26-week, double-blind, uncontrolled exten-
sion trial, the results of measures of mania and overall severity of
illness indicated improvement over time. However, the conclusiveness
of such results is confounded by the uncontrolled nature of the trial
design.
4.1. Limitations
This study had noteworthy strengths, including a relatively large
sample size, double-blind treatment, extended treatment duration, and
long-term TEAE monitoring. However, this study also had noteworthy
limitations, including the absence of a comparator group throughout
the 26-week extension period, restricting conclusions, arguably more
with respect to eﬃcacy than with respect to safety/tolerability.
Moreover, this trial was not powered for direct comparisons of ASN
5 mg bid versus 10 mg bid, making conclusions regarding dose-
dependency of outcomes particularly challenging. Pharmacokinetic
data was not collected, so plasma levels of the drug following long-
term treatment are not available. Clinically signiﬁcant weight gain
(≥7% increase) was not evaluated from extension trial baseline to
endpoint which prohibits drawing conclusions related to the potential
stabilization of weight change. Further, an extension study tends to
include patients who responded to the drug and in whom the drug was
tolerated and reasonably safe.
It should also be noted that our ﬁndings may not be applicable to
more general bipolar disorder populations, owing to the trial's inclu-
sion and exclusion criteria. Furthermore, it needs to be kept in mind
that patients were enrolled based on the DSM-IV-TR diagnostic
criteria, which have since been updated in Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5), limiting inter-
pretation of our ﬁndings with respect to DSM-5 nosology. For example,
DSM-IV-TR deﬁned mixed states as the simultaneous presence of both
threshold major depressive and manic episodes (DSM-IV-TR., 2000),
whereas DSM-5 has replaced the diagnosis of mixed episode with the
more inclusive mixed features (≥3 opposite pole symptoms) speciﬁer
that can be applied to threshold episodes of mania, hypomania, and
even major depression (American Psychiatric Association, 2013).
Although it is unclear how results of a clinical study conducted using
DSM-IV criteria for manic and mixed episodes should be interpreted in
the context of DSM-5 (which would diagnose manic episodes without
and with mixed features, but not mixed episodes), the emphasis of the
current study on safety/tolerability rather than eﬃcacy may mitigate
this limitation.
5. Conclusion
Long-term treatment with ASN 5 and 10 mg bid was generally safe
and well tolerated in adults with an acute manic or mixed episode
associated with bipolar I disorder treated for up to 29 weeks. No dose-
dependence for predeﬁned TEAEs was apparent, and SAEs were
primarily due to patients’ underlying bipolar I disorder. In addition,
the metabolic eﬀects of ASN in this uncontrolled trial appear to be
consistent with ﬁndings from earlier trials.
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